title: Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
abstract: We have previously reported that 90K/Mac-2 binding protein (M2BP) was highly expressed in lung cancer and that M2BP-specific immunity was observed in many of cancer patients. In this study, we analyzed the ability of 11 M2BP-derived oligopeptides with an HLA-A*0201-binding motif to induce M2BP-specific cytotoxic T lymphocytes (CTL) from peripheral blood lymphocytes of normal donors by in vitro stimulation. One of the CTLs that were induced using M2BP216-224 (RIDITLSSV) produced interferon-gamma in response to HLA-A2-positive T2 cells pulsed with the same peptide and lysed MDA-MB-231 cells expressing both M2BP and HLA-A2. The cytolytic activities were blocked by antibodies against HLA class I or CD8. These findings suggest that M2BP216-224 is naturally processed from the native M2BP in cancer cells and recognized by M2BP-specific CTLs in an HLA-A2 restriction. We first identified M2BP-derived CTL epitopes that may be useful as a target antigenic epitope in clinical immunotherapy of cancer.
authors.affiliation: Department of Surgery, Shiga University of Medical Science, Otsu, Japan.
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Ozaki
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kontani
authors.forename: Koji
authors.initials: K
authors.lastname: Teramoto
authors.forename: Takuya
authors.initials: T
authors.lastname: Fujita
authors.forename: Noriaki
authors.initials: N
authors.lastname: Tezuka
authors.forename: Satoru
authors.initials: S
authors.lastname: Sawai
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Shozo
authors.initials: S
authors.lastname: Fujino
authors.forename: Tohru
authors.initials: T
authors.lastname: Asai
authors.forename: Iwao
authors.initials: I
authors.lastname: Ohkubo
mesh_terms: D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000276:immunology* / Q000378:metabolism; D014408:Biomarkers, Tumor; D002352:Carrier Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology* / Q000378:metabolism; D006023:Glycoproteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015234:HLA-A Antigens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis; D009363:Neoplasm Proteins / Q000276:immunology / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D010446:Peptide Fragments / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism; D016326:Extracellular Matrix Proteins
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D018984:Epitopes, T-Lymphocyte; D006023:Glycoproteins; D015234:HLA-A Antigens; D007371:Interferon-gamma; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D012333:RNA, Messenger; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins